Shuttle Pharmaceuticals Holdings, Inc. announced on November 13, 2026, the issuance of pre-funded warrants for 6,693,740 common shares at an exercise price of $0.001 per share. The company received no additional cash for these warrants, which were issued following the satisfaction of specific Milestone Events. The firm also established a mandatory registration schedule for these shares, running from January 31, 2027, through May 1, 2027.
On November 13, 2026, the company determined the Milestone Events were satisfied and issued pre-funded warrants exercisable immediately for up to 6,693,740 common shares at $0.001 per share with no cash consideration received, a large potential share count increase for a small Nasdaq company. The SPA Amendment also locks in mandatory registration statements (by January 31 to May 1, 2027) that will make these resale shares freely tradable, adding overhang. Dilution of this size typically pressures a micro-cap price.
- ▼ Issuance of pre-funded warrants for 6,693,740 shares at $0.001 exercise price on November 13, 2026 with no cash consideration
- ▼ Mandatory resale registration statements due January 31, 2027 through May 1, 2027 for Conversion, Warrant and Milestone Shares
- ▲ Potential dilution only materializes when warrants are exercised and resale registrations become effective
- ▲ Registration statements could be delayed up to 90 days if the SEC reviews them